A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients
Por:
Ortiz Salvador JM, Saneleuterio Temporal M, Magdaleno Tapial J, Manel VP, Conrad PM, Sahuquillo Torralba A, Mateu-Puchades, A, Pitarch-Bort, G, Mari-Ruiz, J, Mataix Díaz J, Montesinos Villaescusa E, Miralles-Botella, J, Garcia-Fernandez, L, Martorell Calatayud A, Belinchon-Romero, I, Sánchez Carazo JL and Pérez Ferriols A
Publicada:
1 ago 2019
Ahead of Print:
11 mar 2019
Resumen:
Background: Secukinumab is a first-in-class interleukin 17A monoclonal
antibody that has demonstrated an excellent safety and efficacy profile
in phase 3 studies.
Objective: To evaluate the effectiveness of secukinumab in daily
clinical practice and to understand the clinical and epidemiologic
characteristics of patients treated with secukinumab in clinical
settings.
Methods: In this multicenter prospective observational study, we
recruited adult patients with moderateto- severe plaque psoriasis from
12 hospitals in Spain during January-December 2016. These patients were
treated with secukinumab and prospectively followed at 12-week intervals
for 52 weeks.
Results: In total, 158 patients were recruited to the study. A Psoriasis
Area and Severity Index (PASI) score improvement $ 75% over baseline
(PASI-75) was achieved by 57%, 83.5%, 89%, and 78.5% of patients at
weeks 4, 12, 24, and 52, respectively. PASI-90 was achieved in 27.8%,
62%, 64.6%, and 63.2% of patients at weeks 4, 12, 24, and 52,
respectively; PASI-75 and PASI-90 responders were significantly more
common among patients with a body mass index < 30 kg/cm(2) and patients
without previous biologic therapy failures.
Limitations: Observational study. Time from onset of psoriasis was not
evaluated.
Conclusion: Secukinumab is a safe treatment with effectiveness rates
similar to those found in its phase 3 studies. These rates endure up to
a year from start of treatment.
Filiaciones:
Ortiz Salvador JM:
University General Hospital of Valencia, Dermatology Department
Saneleuterio Temporal M:
University General Hospital of Valencia, Dermatology Department
Magdaleno Tapial J:
University General Hospital of Valencia, Dermatology Department
Manel VP:
Arnau de Vilanova Hospital of Valencia, Dermatology Department
Conrad PM:
La Fe Hospital of Valencia, Dermatology Department
Sahuquillo Torralba A:
La Fe Hospital of Valencia, Dermatology Department
Mateu-Puchades, A:
Dr. Peset Hospital of Valencia, Dermatology Department
Pitarch-Bort, G:
General Hospital of Castellon, Dermatology Department
Mari-Ruiz, J:
La Ribera Hospital, Alzira, Dermatology Department
Mataix Díaz J:
Marina Baixa Hospital, Alicante, Dermatology Department
Montesinos Villaescusa E:
Valencia Clinic Hospital, Dermatology Department
Miralles-Botella, J:
San Juan de Alicante Hospital, Dermatology Department
Garcia-Fernandez, L:
Elda Hospital, Dermatology Department
Martorell Calatayud A:
Manises Hospital, Dermatology Department
:
General Hospital of Alicante, Dermatology Department
Sánchez Carazo JL:
University General Hospital of Valencia, Dermatology Department
Pérez Ferriols A:
University General Hospital of Valencia, Dermatology Department
hybrid
|